Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 2.
doi: 10.1681/ASN.0000000877. Online ahead of print.

Albuminuria Is the Key Driver of Kidney Benefit with Aldosterone Receptor Antagonists in Type 2 Diabetes

João Pedro Ferreira  1   2 , Luís Mendonça  1 , Pedro Marques  1 , João Sérgio Neves  1 , Faiez Zannad  2 , Milton Packer  3
Affiliations

Albuminuria Is the Key Driver of Kidney Benefit with Aldosterone Receptor Antagonists in Type 2 Diabetes

João Pedro Ferreira et al. J Am Soc Nephrol. .
No abstract available

Keywords: albuminuria; aldosterone.

PubMed Disclaimer

References

    1. Vaduganathan M, Filippatos G, Claggett BL, et al. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med. 2024;30(12):3758–3764. doi: 10.1038/s41591-024-03264-4 - DOI
    1. Vaduganathan M, Neuen BL, McCausland F, et al. Why has it been challenging to modify kidney disease progression in patients with heart failure? J Am Coll Cardiol. 2024;84(22):2241–2245. doi: 10.1016/j.jacc.2024.08.034 - DOI
    1. Mendonça L, Neves JS, Testani J, Zannad F, Ferreira JP. MRAs, SGLT2 inhibitors and kidney outcomes in CKD and HF: differences in diseases, drugs, or both? JACC Heart Fail. 2025;13(8):102514. doi: 10.1016/j.jchf.2025.102514 - DOI
    1. Butt JH, Jhund PS, Henderson AD, et al. Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial. Eur J Heart Fail. 2025;27(7):1326–1341. doi: 10.1002/ejhf.3649 - DOI
    1. Bakris GL, Agarwal R, Anker SD, et al.; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. New Engl J Med. 2020;383(23):2219–2229. doi: 10.1056/NEJMoa2025845 - DOI

Associated data

LinkOut - more resources